Cyrus Desouza, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1346298148
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,526 of the $85,689 with a category attached, or 69.5%. 14 manufacturers reported payments, led by Novo Nordisk at 49.1% of the total. Reporting peaked in 2019 at $34,454 and has fallen 65.5% since, to $11,893 in 2025. Among endocrinology, diabetes & metabolism clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $973.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$42K
- Novo Nordisk AS$22K
- Eli Lilly$11K
- Bayer$8K
- AstraZeneca$1K
- Abbott$600
- plus $976 from 8 others
Across 4,156 payments — averaging $857.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2.2M
- Novartis$539K
- Eli Lilly$326K
- Sanofi US Services Inc.$134K
- Kowa Research Institute, Inc.$97K
- Amgen$80K
- plus $173K from 8 others
What the payments were for
- Consulting fees$59,52669%
- Travel & lodging$22,74727%
- Food & beverage$3,4164%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $42,053 |
| Novo Nordisk AS | 17 | $22,024 |
| Eli Lilly | 17 | $11,246 |
| Bayer | 14 | $7,682 |
| AstraZeneca | 2 | $1,109 |
| Abbott | 2 | $600 |
| Dexcom, Inc. | 2 | $365 |
| Ascendis Pharma Endocrinology Inc | 1 | $161 |
| Boehringer Ingelheim | 1 | $136 |
| BD | 1 | $108 |
| Corcept Therapeutics | 1 | $102 |
| Medtronic | 1 | $62 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$9,760
- Non-Covered$5,522
- Tresiba$3,060
- Kerendia$1,755
- FARXIGA$1,074
- DEXCOM G6 TRANSMITTER$365
- Afinion 2$300
- ALERE AFINION HBA1C CONTROL$300
- Yorvipath$161
- Korlym$102
How this compares
$85,689 in reported general payments places this provider in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
- Mohsen ZenaOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.